Clobazam for patients with Lennox–Gastaut syndrome and epilepsy

References

• Gastaut H. Exceptional and unrecognized antiepileptic properties of a commercial anxiolytic: clobazam [in French]. Concours Med.100, 3697–3701 (1978).
   Google Scholar
• Gastaut H, Low MD. Antiepileptic properties of clobazam, a 1–5 benzodiazepine, in man. Epilepsia20(4), 437–446 (1979).
   PubMed Web of Science ®Google Scholar
• Fielding S, Lal H. A review of the animal pharmacology of clobazam: an update. Drug Dev. Res.2(S1), 17–21 (1982).
   Google Scholar
• Canadian Clobazam Cooperative Group. Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia32(3), 407–416 (1991).
   PubMed Web of Science ®Google Scholar
• Chapman AG, Horton RW, Meldrum BS. Anticonvulsant action of a 1,5-benzodiazepine, clobazam, in reflex epilepsy. Epilepsia19(3), 293–299 (1978).
   PubMed Web of Science ®Google Scholar
• Ng YT, Collins SD. Clobazam. Neurotherapeutics4(1), 138–144 (2007).
   PubMed Web of Science ®Google Scholar
• Sugai K. Clobazam as a new antiepileptic drug and clorazepate dipotassium as an alternative antiepileptic drug in Japan. Epilepsia45(Suppl. 8), 20–25 (2004).
   PubMed Web of Science ®Google Scholar
• Sankar R. GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs26(3), 229–244 (2012).
   PubMed Web of Science ®Google Scholar
• Doi T, Ueda Y, Tokumaru J, Willmore LJ. Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe(+++)-induced epileptic rats. Brain Res. Mol. Brain Res.142(2), 91–96 (2005).
   PubMedGoogle Scholar
• Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol. Rev.60(3), 243–260 (2008).
   PubMed Web of Science ®Google Scholar
• Nakajima H. A pharmacological profile of clobazam (Mystan), a new antiepileptic drug [In Japanese]. Nippon Yakurigaku Zasshi118(2), 117–122 (2001).
   PubMedGoogle Scholar
• Leonard B. A review of the pharmacological properties of the benzodiazepine anxiolytics. In: Benzodiazepines. Trimble MR, Hindmarch I (Eds). Wrightson Biomedical Publishing Inc., Petersfield, UK, 1–16 (2000).
   Google Scholar
• Kinoshita M, Ikeda A, Begum T, Terada K, Shibasaki H. Efficacy of low-dose, add-on therapy of clobazam (CLB) is produced by its major metabolite, N-desmethyl-CLB. J. Neurol. Sci.263(1–2), 44–48 (2007).
   PubMedGoogle Scholar
• Sennoune S, Mesdjian E, Bonneton J, Genton P, Dravet C, Roger J. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther. Drug Monit.14(4), 269–274 (1992).
   PubMed Web of Science ®Google Scholar
• Contin M, Riva R, Albani F, Baruzzi AA. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther. Drug Monit.21(6), 604–608 (1999).
   PubMedGoogle Scholar
• Fielding S, Hoffmann I. Pharmacology of anti-anxiety drugs with special reference to clobazam. Br. J. Clin. Parmacol.7(S1), 7S–15S (1979).
   PubMedGoogle Scholar
• Greenblatt DJ, Divoll M, Puri SK, Ho I, Zinny MA, Shader RI. Clobazam kinetics in the elderly. Br. J. Clin. Pharmacol.12(5), 631–636 (1981).
   PubMed Web of Science ®Google Scholar
• Haigh JR, Pullar, T, Gent, JP, Dailley C, Feely M. N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy. Br. J. Clin. Pharmacol.23(2), 213–218 (1987).
   PubMedGoogle Scholar
• Nakamura F, Suzuki S, Nishimura S, Yagi K, Seino M. Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture. Epilepsia37(8), 728–735 (1996).
   PubMedGoogle Scholar
• Fisher JL. Interactions between modulators of the GABAA receptor: stiripentol and benzodiazepines. Eur. J. Pharmacol.654(2), 160–165 (2011).
   PubMed Web of Science ®Google Scholar
• Brogden RN, Heel RC, Speight TM, Avery GS. Clobazam: a review of its pharmacological properties and therapeutic use in anxiety. Drugs20(3), 161–178 (1980).
   PubMed Web of Science ®Google Scholar
• Rupp W, Badian M, Christ O et al. Pharmacokinetics of single and multiple doses of clobazam in humans. Br. J. Clin. Pharmacol.7(S1), 51S–57S (1979).
   PubMed Web of Science ®Google Scholar
• Anderson GD, Miller JW. Benzodiazepines: chemistry, biotransformation, and pharmacokinetics. In: Antiepileptic Drugs. Levy RH, Mattson RH, Meldrum BS, Peracca E (Eds). Lippincott Williams & Wilkins, PA, USA, 187–205 (2002).
   Google Scholar
• Divoll M, Greenblatt DJ, Ciraulo DA, Puri SK, Ho I, Shader RI. Clobazam kinetics: intrasubject variability and effect of food on adsorption. J. Clin. Pharmacol.22(1), 69–73 (1982).
   PubMed Web of Science ®Google Scholar
• Cenraud B, Guyot M, Levy RH et al. No effect of food intake on clobazam absorption. Br. J. Clin. Pharmacol.16(6), 728–730 (1983).
   PubMed Web of Science ®Google Scholar
• Contin M, Sangiorgi S, Riva R, Parmeggiani A, Albani F, Baruzzi A. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther. Drug Monit.24(6), 737–741 (2002).
   PubMed Web of Science ®Google Scholar
• Robertson MM. The place of clobazam in the treatment of epilepsy: an update. Hum. Psychopharmacol.10(Suppl. 1), S43–S63 (1995).
   Google Scholar
• Tolbert DS, Reid M, Walzer A et al. Oral pharmacokinetics of clobazam in normal subjects. AAPS Annual Meeting and Exposition, Los Angeles, CA, USA, 8–12 November 2009.
   Google Scholar
• Tedeschi G, Riva R, Baruzzi A. Clobazam plasma concentrations: pharmacokinetic study in healthy volunteers and data in epileptic patients. Br. J. Clin. Pharmacol.11(6), 619–622 (1981).
   PubMed Web of Science ®Google Scholar
• Dehnerdt M, Boenigk H. Clobazam (Frisium) for the treatment of complications of epilepsy [in German]. In: Epilepsy: Psychological Aspects, Post-traumatic Epilepsy, Drug Treatment, Diagnostic Methods. Meeting of the German Section of the International League Against Epilepsy in Berlin. Remschmidt H, Rentz R, Jungmann JE (Eds). Georg Thieme, Stuttgart, Germany, 172–175 (1980).
   Google Scholar
• Bun H, Monjanel-Mouterde S, Noel F, Durand A, Cano JP. Effects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam. Pharmacol. Toxicol.67(2), 136–140 (1990).
   PubMedGoogle Scholar
• Cocks A, Critchley EMR, Hayward HW. The effects of clobazam on the blood levels of sodium valproate. In: Clobazam: Human Psychopharmacology and Clinical Applications. Hindmarch I, Stonier PD, Trimble MR (Eds). Royal Society of Medicine, London, UK, 155–157 (1985).
   Google Scholar
• Yagi K, Seino M, Takeda A et al. Open clinical trials of NH-15 (clobazam) in refractory epilepsies: early Phase II study and long-term study. Jpn. J. Neuropsychopharmacol.17, 161–173 (1995).
   Google Scholar
• Theis JG, Koren G, Daneman R et al. Interactions of clobazam with conventional antiepileptics in children. J. Child Neurol.12(3), 208–213 (1997).
   PubMedGoogle Scholar
• Luszczki JJ, Trojnar MK, Ratnaraj N, Patsalos PN, Czuczwar SJ. Interactions of stiripentol with clobazam and valproate in the mouse maximal electroshock-induced seizure model. Epilepsy Res.90(3), 188–198 (2010).
   PubMed Web of Science ®Google Scholar
• Shimizu H, Kawasaki J, Yuasa S, Tarao Y, Kumagai S, Kanemoto K. Use of clobazam for the treatment of refractory complex partial seizures. Seizure12(5), 282–286 (2003).
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Fröscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia43(4), 365–385 (2002).
   PubMed Web of Science ®Google Scholar
• Bardy AH, Seppälä T, Salokorpi T, Granström ML, Santavuori P. Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy. Brain Dev.13(3), 174–179 (1991).
   PubMed Web of Science ®Google Scholar
• Guberman A. Monotherapy or polytherapy for epilepsy? Can. J. Neurol. Sci.25(4), S3–S8 (1998).
   PubMedGoogle Scholar
• Genton P, Nguyen VH, Mesdjian E. Carbamazepine intoxication with negative myoclonus after the addition of clobazam. Epilepsia39(10), 1115–1118 (1998).
   PubMedGoogle Scholar
• Zifkin B, Sherwin A, Andermann F. Phenytoin toxicity due to interaction with clobazam. Neurology41(2 Pt 1), 313–314 (1991).
   PubMed Web of Science ®Google Scholar
• Bauer J, Pfeiffer C, Burr W. Which factors have an impact on levetiracetam serum concentrations? An analysis in 163 patients with epilepsy [In German]. Nervenarzt81(4), 391–395 (2010).
   PubMedGoogle Scholar
• Grigoleit HG, Hajdú P, Hundt HK et al. Pharmacokinetic aspects of the interaction between clobazam and cimetidine. Eur. J. Clin. Pharmacol.25(1), 139–142 (1983).
   PubMedGoogle Scholar
• Gerbal-Chaloin S, Pascussi J-M, Pichard-Garcia L et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab. Dispos.29(3), 242–251 (2001).
   PubMed Web of Science ®Google Scholar
• Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J. Pharmacol. Exp. Ther.299(3), 849–857 (2001).
   PubMed Web of Science ®Google Scholar
• Wang LS, Zhou G, Zhu B et al. St John’s wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin. Pharm. Ther.75(3), 191–197 (2004).
   PubMed Web of Science ®Google Scholar
• Goshman L, Fish J, Roller K. Clinically significant P450 drug interactions. J. Pharm. Soc. Wis.1999, 23–38 (1999).
   Google Scholar
• Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem. Biophys. Res. Commun.175(3), 1112–1118 (1991).
   PubMed Web of Science ®Google Scholar
• Conry JA, Ng YT, Paolicchi JM et al. Clobazam in the treatment of Lennox–Gastaut syndrome. Epilepsia50(5), 1158–1166 (2009).
   PubMed Web of Science ®Google Scholar
• Kilpatrick C, Bury R, Fullinfaw R, Moulds R. Clobazam in the treatment of epilepsy. Clin. Exp. Neurol.23, 139–144 (1987).
   PubMedGoogle Scholar
• Koeppen D, Baruzzi A, Capozza M et al. Clobazam in therapy-resistant patients with partial epilepsy: a double-blind placebo-controlled crossover study. Epilepsia28(5), 495–506 (1987).
   PubMed Web of Science ®Google Scholar
• Schmidt D, Rohde M, Wolf P, Roeder-Wanner U. Clobazam for refractory focal epilepsy: a controlled trial. Arch. Neurol.43(8), 824–826 (1986).
   PubMedGoogle Scholar
• Keene DL, Whiting S, Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can. J. Neurol. Sci.17(3), 317–319 (1990).
   PubMed Web of Science ®Google Scholar
• Rose W, Kirubakaran C, Scott JX. Intermittent clobazam therapy in febrile seizures. Indian J. Pediatr.72(1), 31–33 (2005).
   PubMedGoogle Scholar
• Allen JW, Oxley J, Robertson MM, Trimble MR, Richens A, Jawad SS. Clobazam as adjunctive treatment in refractory epilepsy. Br. Med. J.186(6373), 1246–1247 (1983).
   Google Scholar
• Ng YT, Conry JA, Drummond R et al. Randomized, Phase III study results of clobazam for seizures associated with Lennox–Gastaut syndrome. Neurology77(15), 1473–1481 (2011).
   PubMed Web of Science ®Google Scholar
• Buchanan N. Clobazam in the treatment of epilepsy: prospective follow-up to 8 years. J. R. Soc. Med.86(7), 378–380 (1993).
   PubMed Web of Science ®Google Scholar
• Watanabe M, Yagi K, Ohtahara S, Seino M. Clinical study of a new antiepileptic drug, clobazam, on efficacy and resistance in refractory epilepsies. J. Jpn. Epil. Soc.20(1), 11–18 (2002).
   Google Scholar
• Munn R, Camfield P, Camfield C, Dooley J. Clobazam for refractory childhood seizure disorders – a valuable supplementary drug. Can. J. Neurol. Sci.15(4), 406–408 (1988).
   PubMed Web of Science ®Google Scholar
• Montenegro MA, Cendes F, Noronha AL et al. Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy. Epilepsia42(4), 539–542 (2001).
   PubMed Web of Science ®Google Scholar
• Singh A, Guberman AH, Boisvert D. Clobazam in long-term epilepsy treatment: sustained responders versus those developing tolerance. Epilepsia36(8), 798–803 (1995).
   PubMed Web of Science ®Google Scholar
• Shorvon SD. The use of clobazam, midazolam, and nitrazepam in epilepsy. Epilepsia39(Suppl. 1), S15–S23 (1998).
   PubMedGoogle Scholar
• Wildin JD, Pleuvry BJ, Mawer GE, Onon T, Millington L. Respiratory and sedative effects of clobazam and clonazepam in volunteers. Br. J. Clin. Pharmacol.29(2), 169–177 (1990).
   PubMedGoogle Scholar
• Khosroshahi N, Faramarzi F, Salamati P, Haghighi SM, Kamrani K. Diazepam versus clobazam for intermittent prophylaxis of febrile seizures. Indian J. Pediatr.78(1), 38–40 (2011).
   PubMedGoogle Scholar
• McKernan RM, Rosahl TW, Reynolds DS et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat. Neurosci.3(6), 587–592 (2000).
   PubMed Web of Science ®Google Scholar
• Mills JK, Lewis TG, Mughal K, Ali I, Ugur A, Whitehouse WP. Retention rate of clobazam, topiramate and lamotrigine in children with intractable epilepsies at 1 year. Seizure20(5), 402–405 (2011).
   PubMedGoogle Scholar
• Montenegro MA, Arif H, Nahm EA, Resor SR Jr, Hirsch LJ. Efficacy of clobazam as add-on therapy for refractory epilepsy: experience at a US epilepsy center. Clin. Neuropharmacol.31(6), 333–338 (2008).
   PubMedGoogle Scholar
• Robertson MM. Current status of the 1,4- and 1,5- benzodiazepines in the treatment of epilepsy: the place of clobazam. Epilepsia27(Suppl. 1), S27–S41 (1986).
   PubMedGoogle Scholar
• Dalby MA. Clobazam in resistant epilepsy: a retrospective survey. In: Clobazam: Human Psychopharmacology and Clinical Applications. Hindmarch I, Stonier PD, Trimble MR (Eds). Royal Society of Medicine, London, UK, 189 (1985).
   Google Scholar
• Watanabe M, Yagi K, Seino M. An open clinical trial of a newly developed antiepileptic drug, clobazam, on treatment-resistant epileptic seizures [In Japanese]. Saishin Igaku34, 757–766 (1992).
   Google Scholar
• Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia39(9), 952–959 (1998).
   PubMed Web of Science ®Google Scholar
• Heller AJ, Ring HA, Reynolds EH. Factors relating to dramatic response to clobazam in refractory epilepsy. Epilepsy Res.2(4), 276–280 (1988).
   PubMedGoogle Scholar
• Haigh JR, Gent JP, Garratt JC et al. Disappointing results of increasing benzodiazepine dose after the development of anticonvulsant tolerance. J Neurol. Neurosurg. Psychiatry51(7), 1008–1009 (1988).
   PubMedGoogle Scholar
• Gastaut H, Tinuper P, Aguglia U, Lugaresi E. Treatment of certain forms of status epilepticus by means of single dose of clobazam [In French]. Rev. Electroencephalogr. Neurophysiol.14(3), 203–206 (1984).
   PubMedGoogle Scholar
• Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia34(3), 453–468 (1993).
   PubMed Web of Science ®Google Scholar
• Markand ON. Lennox–Gastaut syndrome (childhood epileptic encephalopathy). J. Clin. Neurophysiol.20(6), 426–441 (2003).
   PubMed Web of Science ®Google Scholar
• Beaumanoir A, Darvet C. The Lennox–Gastaut syndrome. In: Epileptic Syndromes in Infancy, Childhood and Adolescence (2nd Edition). Roger J, Bureau M, Dravet CH, Dreifuss FE, Perret AWP (Eds). John Libbey Eurotext, London, UK, 115–132 (1992).
   Google Scholar
• Crumrine PK. Lennox–Gastaut syndrome. J. Child Neurol.17(Suppl. 1), S70–S75 (2002).
   PubMed Web of Science ®Google Scholar
• Wheless JW. Nonpharmacologic treatment of the catastrophic epilepsies of childhood. Epilepsia45(Suppl. 5), 17–22 (2004).
   PubMedGoogle Scholar
• Critchley EMR, Vakil SD, Hayward HW, Owen MV, Cocks A. Double-blind clinical study of clobazam in refractory epilepsy. In: Clobazam. Hindmarch I, Stonier PD (Eds). Royal Society of Medicine, London, UK, 159–163 (1981).
   Google Scholar
• Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: tolerance avoided. J. Neurol. Neurosurg. Psychiatry47(12), 1279–1282 (1984).
   PubMed Web of Science ®Google Scholar
• Callaghan N, Goggin T. Clobazam as adjunctive treatment in drug resistant epilepsy – report on an open prospective study. Ir. Med. J.77(8), 240–244 (1984).
   PubMedGoogle Scholar
• Andrade R, García-Espinosa A, Machado-Rojas A, García-González ME, Trápaga-Quincoses O, Morales-Chacón LM. A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [In Spanish]. Rev. Neurol.49(11), 581–586 (2009).
   PubMed Web of Science ®Google Scholar
• Jan MM, Shaabat AO. Clobazam for the treatment of intractable childhood epilepsy. Saudi Med. J.21(7), 622–624 (2000).
   PubMedGoogle Scholar
• Silva RC, Montenegro MA, Guerreiro CA, Guerreiro MM. Clobazam as add-on therapy in children with epileptic encephalopathy. Can. J. Neurol. Sci.33(2), 209–213 (2006).
   PubMedGoogle Scholar
• Figueroa D, Adlerstein L, Manterola A. Clobazam in refractory epilepsies of children [In Spanish]. Rev. Chil. Pediatr.55(6), 401–405 (1984).
   PubMedGoogle Scholar
• Dávila-Gutiérrez G, Mondragón-Pineda A, Alcalá-Negrete H. Usefulness of clobazam in the treatment of refractory epilepsy in children [In Spanish]. Bol. Med. Hosp. Infant Mex.47(10), 694–647 (1990).
   PubMedGoogle Scholar
• Gastaut H. The effect of benzodiazepines on chronic epilepsy in man (with particular reference to clobazam). In: Clobazam. Hindmarch I, Stonier P (Eds). Royal Society of Medicine, London, UK, 141–150 (1981).
   Google Scholar
• Bravaccio F, D’Ambrosio G, De Rosa A, Tata MR, Volpe E. The anti-epileptic properties of a diazepine drug (clobazam). Preliminary results. [In Italian]. Acta. Neurol. Quad.39, 58–64 (1979).
   Google Scholar
• Pechadre JC, Beudin P, Devoize JL, Gibert J. [Anti-epileptic effect of clobazam in Lennox–Gastaut syndrome]. Encephale7(2), 181–190 (1981).
   PubMedGoogle Scholar
• Franceschi M, Ferini-Strambi L, Mastrangelo M. Clobazam in drug-resistant and alcoholic withdrawal seizures. Clin. Study J.20, 119–125 (1983).
   Google Scholar
• Guberman A, Couture M, Blaschuk K, Sherwin A. Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations. Can. J. Neurol. Sci.17(3), 311–316 (1990).
   PubMed Web of Science ®Google Scholar
• Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ327(7429), 1459–1461 (2003).
   PubMed Web of Science ®Google Scholar
• Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. Topiramate YL Study Group. Neurology52(9), 1882–1887 (1999).
   PubMed Web of Science ®Google Scholar
• Felbamate Study Group in Lennox–Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox–Gastaut syndrome). N. Engl. J. Med.328(1), 29–33 (1993).
   PubMed Web of Science ®Google Scholar
• Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox–Gastaut syndrome. Lamictal Lennox–Gastaut Study Group. N. Engl. J. Med.337(25), 1807–1812 (1997).
   PubMed Web of Science ®Google Scholar
• Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology70(21), 1950–1958 (2008).
   PubMed Web of Science ®Google Scholar
• Ng YT. A case of symptomatic, lesional epilepsy (hypothalamic hamartoma) masquerading as a generalized epilepsy with Lennox–Gastaut syndrome. Sem. Pediatr. Neurol.17(1), 13–15 (2010).
   PubMedGoogle Scholar
• Wyllie E, Lachhwani DK, Gupta A et al. Successful surgery for epilepsy due to early brain lesions despite generalized EEG findings. Neurology69(4), 389–397 (2007).
   PubMedGoogle Scholar